Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research
David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.
Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer
March 10th 2020David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.
Dr. Woyach on the Design of the Ongoing Alliance A041702 Trial in CLL
February 5th 2020Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).
Novel Surgical Technique Alleviates Adverse Events After Amputation in Patients With Cancer
Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.